Sol-Gel Technologies Ltd. (SLGL)
SLGLNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$61.88
+0.1400 (+0.23%) today
Regular session, Nov 10, 1:53 PM ET
- Market cap
- $202.60m
- P/E
- –
- EPS, last 4 quarters
- $-5.64
- Dividend yield
- –
- Day range
- $61.00 to $62.80
- 52-week range
- $28.81 to $97.97
- Average volume
- 45.7k
- Previous close
- $61.74
Analysts
4 coveringStrong Buy3 buy, 1 hold, 0 sell
Targets a year out average $168.33, +172.0% from here
Earnings
next estimate $-1.54Next report Nov 19, 2026
Sep 2025
-1.9%
Dec 2025
-374.4%
Mar 2026
–
Jun 2026
+51.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2017 | Dec 2017 |
|---|---|---|
| Revenue | – | $174.0k |
| Gross profit | – | $174.0k |
| Operating income | -$14.33m | -$5.46m |
| Net income | -$14.29m | -$5.45m |
News
8 latest- Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesZacks · Oct 29, 2026
- New Strong Buy Stocks for October 16thZacks · Oct 16, 2026
- Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome DataMarketBeat · Oct 14, 2026
- Cantor Fitzgerald Initiates Coverage of Sol-Gel Technologies at OverweightFintel · Oct 14, 2026
- SolGel Technologies (SLGL) Upgraded to Buy: Here's WhyZacks · Oct 8, 2026
- SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks · Sep 17, 2026
- Sol-Gel Posts Net Loss In Q2; Phase 3 Gorlin Results Due In November 2026 RTTNews · Aug 20, 2026
- MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass EstimatesZacks · Aug 13, 2026
The company
Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serios skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin Syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- sol-gel.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.